VibroSense Wins Australian Patent Acceptance for Chemotherapy Nerve Damage Prediction Method
- VibroSense Dynamics received a Notice of Acceptance from IP Australia for its patent application covering prediction of chemotherapy-induced peripheral neuropathy.
- The method uses low-frequency vibration perception detection to identify patients at elevated risk of chemotherapy-related nerve damage, potentially supporting treatment adjustments.
- Patent acceptance supports future commercialization in Australia.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VibroSense Dynamics AB published the original content used to generate this news brief on November 18, 2026, and is solely responsible for the information contained therein.